Financials

Discussions Technicals Seasonals

ORIONINFU fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Orion Infusion Ltd. engages in the manufacture of large volume parenteral and other injectable products. Its products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. The company was founded by Arzuda Karim and Mohammad Obaidul Karim on May 5, 1983 and is headquartered in Dhaka, Bangladesh.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ORIONINFU does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company